PSEUDOVITELLIFORM MACULOPATHY SECONDARY TO BRAF AND MEK INHIBITORS IN A PATIENT WITH METASTASIC MELANOMA

被引：0
|
作者：
Alba-Linero, C. [1 ]
Rocha De Lossada, C. [1 ]
Delgado-Fernandez, A. S. [1 ]
Jodar-Marquez, M. [1 ]
Calvo De Mora, M. Rodriguez [1 ]
Berciano-Guerrero, M. A. [2 ]
机构：
[1] Hosp Reg Malaga, Plaza Hosp Civil, Ophthalmol Dept, Malaga 29009, Spain
[2] Hosp Reg Malaga, Oncol Dept, Malaga, Spain
来源：
JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS | 2019年 / 33卷 / 05期
关键词：
neuroepithelial detachment; metastasic melanoma; BRAF inhibitors; MEK inhibitors; pseudovitelliform;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1497 / 1500
页数：4
相关论文
共 50 条
  • [41] Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma
    Maria Elena Pisanu
    Marcello Maugeri-Saccà
    Luigi Fattore
    Sara Bruschini
    Claudia De Vitis
    Eugenio Tabbì
    Barbara Bellei
    Emilia Migliano
    Daniela Kovacs
    Emanuela Camera
    Mauro Picardo
    Ziga Jakopin
    Claudia Cippitelli
    Armando Bartolazzi
    Salvatore Raffa
    Maria Rosaria Torrisi
    Franco Fulciniti
    Paolo A. Ascierto
    Gennaro Ciliberto
    Rita Mancini
    Journal of Experimental & Clinical Cancer Research, 37
  • [42] The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma-A Retrospective, Real-World Cohort Study
    Haist, Maximilian
    Stege, Henner
    Ebner, Ronja
    Fleischer, Maria Isabel
    Loquai, Carmen
    Grabbe, Stephan
    CANCERS, 2022, 14 (09)
  • [43] Intermittent Versus Continuous Dosing of MAPK Inhibitors in Treatment of BRAF-Mutated Melanoma
    de Moura, Coralie Reger
    Vercellino, Laetitia
    Jouenne, Fanelie
    Baroudjian, Barouyr
    Sadoux, Aurelie
    Louveau, Baptiste
    Delyon, Julie
    Serror, Kevin
    Goldwirt, Lauriane
    Merlet, Pascal
    Bouquet, Fanny
    Battistella, Maxime
    Lebb, Celeste
    Mourah, Samia
    TRANSLATIONAL ONCOLOGY, 2020, 13 (02): : 275 - 286
  • [44] BRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapy
    Chowdhary, Mudit
    Patel, Kirtesh R.
    Danish, Hasan H.
    Lawson, David H.
    Khan, Mohammad K.
    ONCOTARGETS AND THERAPY, 2016, 9 : 7149 - 7159
  • [45] Efficacy and safety of BRAF/MEK inhibitors in BRAFV600E-mutated anaplastic thyroid cancer: a systematic review and meta-analysis
    Priantti, Jonathan N.
    Rodrigues, Natasha Maranhao Vieira
    de Moraes, Francisco Cezar Aquino
    da Costa, Allyson Guimaraes
    Jezini, Deborah Laredo
    Heckmann, Maria Izabel Ovellar
    ENDOCRINE, 2024, 86 (01) : 284 - 292
  • [46] Panniculitis With Necrotizing Granulomata in a Patient on BRAF Inhibitor (Dabrafenib) Therapy for Metastatic Melanoma
    Ramani, Nisha S.
    Curry, Jonathan L.
    Kapil, Jyoti
    Rapini, Ronald P.
    Tetzlaff, Michael T.
    Prieto, Victor G.
    Torres-Cabala, Carlos A.
    AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2015, 37 (08) : e96 - e99
  • [47] Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction
    Moriceau, Gatien
    Hugo, Willy
    Hong, Aayoung
    Shi, Hubing
    Kong, Xiangju
    Yu, Clarissa C.
    Koya, Richard C.
    Samatar, Ahmed A.
    Khanlou, Negar
    Braun, Jonathan
    Ruchalski, Kathleen
    Seifert, Heike
    Larkin, James
    Dahlman, Kimberly B.
    Johnson, Douglas B.
    Algazi, Alain
    Sosman, Jeffrey A.
    Ribas, Antoni
    Lo, Roger S.
    CANCER CELL, 2015, 27 (02) : 240 - 256
  • [48] BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials
    Fujimura, Taku
    Hidaka, Takanori
    Kambayashi, Yumi
    Aiba, Setsuya
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (02) : 143 - 148
  • [49] BRAF V600 Mutation and BRAF Kinase Inhibitors in Conjunction With Stereotactic Radiosurgery for Intracranial Melanoma Metastases: A Multicenter Retrospective Study
    Mastorakos, Panagiotis
    Xu, Zhiyuan
    Yu, James
    Hess, Judith
    Qian, Jack
    Chatrath, Ajay
    Taylor, Davis G.
    Kondziolka, Douglas
    Warnick, Ronald
    Chiang, Veronica
    Sheehan, Jason
    NEUROSURGERY, 2019, 84 (04) : 868 - 879
  • [50] The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence
    Lemech, Charlotte
    Infante, Jeffrey
    Arkenau, Hendrik-Tobias
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2012, 4 (02) : 61 - 73
12345